As the newly formed cancer service line of HCA, Sarah Cannon is committed to advancing science and transforming care. People who live with cancer – those who work to prevent it, fight it, and survive it – are at the heart of every decision we make.
At Sarah Cannon, there has been a legacy of devotion to cancer research and care. The initial clinical research trials began in Nashville in 1993 under the leadership of Drs. Tony Greco and John Hainsworth. Steady growth through the Minnie Pearl Cancer Research Network led to the formation of the Sarah Cannon Research Institute (SCRI) in 2004 as a joint venture of HCA and Tennessee Oncology. Today, Sarah Cannon is expanding our position in cancer beyond clinical research, providing integrated care across facilities and markets in the United States and the United Kingdom. - See more at: http://sarahcannon.com/cancer-care/index.dot#sthash.D0GL1Vfw.dpuf